<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261387</url>
  </required_header>
  <id_info>
    <org_study_id>LUT-RD-02-01</org_study_id>
    <nct_id>NCT04261387</nct_id>
  </id_info>
  <brief_title>LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients</brief_title>
  <official_title>A Two-Part (Open-Label Followed by Randomized, Double-Blind, Placebo-Controlled) Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of Topically Administered LUT014 for the Treatment of Radiation-Induced Dermatitis in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lutris Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lutris Pharma Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety, tolerability and efficacy of LUT014 gel topically&#xD;
      administered in breast cancer patients who developed radiation dermatitis. Subjects enrolled&#xD;
      to part 1 will be enrolled to receive the study treatment (open label treatment) for 28 days&#xD;
      and will be followed up for 2 months after the completion of study treatment. Subject in Part&#xD;
      2 will be randomized in 1:1 ratio to receive either the study drug or placebo (double-blind&#xD;
      treatment) for qd topical application for 28 days and will be followed up for 2 months after&#xD;
      the completion of study treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE (Part 1 subjects)</measure>
    <time_frame>12 weeks (83 days)</time_frame>
    <description>Common Terminology Criteria for Adverse Events Version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the severity of radiation dermatitis based on self reporting Dermatology QoL questionnaire (Part 2 subjects)</measure>
    <time_frame>14 Days</time_frame>
    <description>Dermatology Life Quality Index questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the severity of radiation dermatitis assessed by CTCAE (Part 1 subjects)</measure>
    <time_frame>12 weeks (83 days)</time_frame>
    <description>CTCAE grading scale for dermatitis radiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the severity of radiation dermatitis assessed by RTOG/EORTC (part 1 subjects)</measure>
    <time_frame>12 weeks (83 days)</time_frame>
    <description>Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the severity of radiation dermatitis based on self reporting Dermatology QoL questionnaire</measure>
    <time_frame>12 weeks (83 days)</time_frame>
    <description>Dermatology Life Quality Index questionnaire (part 1 subjects)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE (Part 2 subjects)</measure>
    <time_frame>12 weeks (83 days)</time_frame>
    <description>CTCAE grading scale for dermatitis radiation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Radiation Dermatitis</condition>
  <arm_group>
    <arm_group_label>LUT014 Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LUT014 Gel topical application to the dermatitis area qd for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for LUT014 Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LUT014 Gel</intervention_name>
    <description>Topical application qd for 28 days</description>
    <arm_group_label>LUT014 Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for LUT014 Gel</intervention_name>
    <description>Matching placebo for qd topical application for 28 days</description>
    <arm_group_label>Placebo for LUT014 Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female subjects diagnosed with stage Tis, T0-T3, N0-N2, M0 Breast Cancer;&#xD;
&#xD;
          2. Subject is ≥18 years at the time of signing the informed consent form (ICF);&#xD;
&#xD;
          3. Radiation dermatitis of Grade 2, based on the NCI CTCAE at the Screening and Baseline&#xD;
             (D0) visits;&#xD;
&#xD;
          4. Completed fractionated radiation therapy for breast prior to first dose of study drug&#xD;
             (Day 0);&#xD;
&#xD;
          5. A score of ≥ 6 reported in the Dermatology Life Quality Index at the Screening and&#xD;
             Baseline Visits;&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;&#xD;
&#xD;
          7. Females of child-bearing potential must have a negative pregnancy test at screening&#xD;
             and must agree to use an effective contraception method* or abstain from sex&#xD;
             throughout the study until Day 83;&#xD;
&#xD;
          8. Expected life expectancy greater than 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Bilateral breast irradiation;&#xD;
&#xD;
          2. Planned internal mammary node irradiation with electrons. Planned photon coverage of&#xD;
             internal mammary chain nodes is acceptable for inclusion in this study;&#xD;
&#xD;
          3. Planned partial breast accelerated irradiation;&#xD;
&#xD;
          4. Any cutaneous infection or significant skin disease at Screening or Baseline (Day 0)&#xD;
             other than the dermatitis in the area(s) irradiated during fractionated radiation&#xD;
             therapy;&#xD;
&#xD;
          5. T4 breast cancer or direct skin involvement by breast cancer;&#xD;
&#xD;
          6. Breast implants or underwent breast reconstruction;&#xD;
&#xD;
          7. Any cancer other than breast cancer within 3 years of Screening, except for carcinoma&#xD;
             in situ of the cervix;&#xD;
&#xD;
          8. Pregnant or lactating;&#xD;
&#xD;
          9. History of active systemic lupus erythematosus or scleroderma that is believed to&#xD;
             increase the risk of developing radiation-induced dermatitis or its severity;&#xD;
&#xD;
         10. Clinically significant co-morbid diseases&#xD;
&#xD;
         11. Treatment with a serine/threonine-protein kinase B-Raf (B-Raf) inhibitor, including&#xD;
             but not limited to Zelboraf® (vemurafenib), Tafinlar® (dabrafenib), Braftovi®&#xD;
             (encorafenib), and Nexavar® (sorafenib), within 30 days or 5 half-lives of the drug&#xD;
             prior to Screening, whichever is longer;&#xD;
&#xD;
         12. Treatment with a topical corticosteroid o the irradiated chest area within 14 days&#xD;
             prior to Baseline (Day 0).&#xD;
&#xD;
         13. Treatment with a systemic corticosteroid within 14 days prior to Baseline (Day 0),&#xD;
             except for low dose systemic corticosteroids (e.g., 8-20 mg dexamethasone or&#xD;
             comparable) given for up to one or two days every two weeks as part of standard of&#xD;
             care for the prevention or treatment of chemotherapy-induced nausea and vomiting&#xD;
             (CINV);&#xD;
&#xD;
         14. Treatment with any investigational drug within 30 days or 5 half-lives of drug prior&#xD;
             to Screening, whichever is longer;&#xD;
&#xD;
         15. Known hypersensitivity to any of the inactive ingredients of the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Columbus Regional Research Institute, Llc</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tenetta Holt</last_name>
      <phone>706-321-0495</phone>
      <email>tholt@iacthealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Willis-Knighton Cancer Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Briana Barrow</last_name>
      <phone>318-212-8671</phone>
      <email>bbarrow@wkhs.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiation dermatitis, dermatitis, breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

